Skip to content
Screener

Cronos Group CRON Reportable Segment — Stock-Based Comp

Similar metrics at other companies

Credo Technology Group Holding Ltd logo
CRDOReportable Segment — Stock-Based Comp
$50.76M+84.6%
Summit Therapeutics logo
SMMTReportable Segment — Stock-Based Comp
$72.79M+556%
QXO, Inc. logo
QXOReportable Segment — Stock-Based Comp
$39.2M+94.1%
Progress Software logo
PRGSReportable Segment — Stock-Based Comp
$20.51M+22.5%
Madrigal Pharmaceuticals, Inc. logo
MDGLReportable Segment — Stock-Based Comp
$28.38M+43.3%
Lifecore Biomedical, Inc. logo
LFCRReportable Segment — Stock-Based Comp
$2.09M

Other financials

Income statement

See full
Revenue$53.0M+58.4%
Gross profit$28.5M+96.2%
Operating income$7.4M+239%
Net income$32.1M+181%
EPS (diluted)$0.09+190%

Balance sheet

See full
Cash & equivalents$467.0M-41.2%
Total debt$1.3M-35.6%
Total equity$1.1B-1.3%
Total assets$1.2B+0.4%

Cash flow

See full
Operating cash flow$24.0M+752%
CapEx$1.7M-54.7%
Free cash flow$22.3M+2,286%

Valuation

See full
Market cap$1.14B+11.7%
Enterprise value$676.36M+194%
P/E16.3×-39.0×
P/S6.4×-1.5×

Profitability

See full
Gross margin45.9%+13.1pp
Operating margin-1.4%-0.7pp
Net margin39.1%+24.9pp
FCF margin27.8%+23.2pp

Returns & leverage

See full
Return on equity6.5%+4.8pp
Debt / equity0.0×
Current ratio16.2×-8.5×

Where this comes from

Reported directly by Cronos Group in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Cronos Group’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001656472-26-000051
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Sales and marketing6,7855,34712,4009,912
Research and development1,2159292,6281,722
General and administrative, excluding transaction costs10,22210,50420,99919,773
Share-based compensation1,5571,3812,8703,469
Depreciation and amortization3798678041,363
Total significant operating expenses20,15819,02839,70136,239
Restructuring costs3087687921,323
Transaction costs581321,54072

Item 1. Financial Statements.

FAQ

What is Cronos Group's reportable segment — stock-based comp?
Cronos Group (CRON) reported reportable segment — stock-based comp of $1.56M in Q2 2026.
How has Cronos Group's reportable segment — stock-based comp changed year-over-year?
Cronos Group's reportable segment — stock-based comp increased by 12.7% year-over-year, from $1.38M to $1.56M.
What is the long-term trend for Cronos Group's reportable segment — stock-based comp?
Over 3 years (2022 to 2025), Cronos Group's reportable segment — stock-based comp has grown at a -22.3% compound annual growth rate (CAGR), from $15.01M to $7.05M.
What does reportable segment — stock-based comp mean?
This metric quantifies the non-cash expense recognized for equity-based awards granted to employees and management within the reportable segment. It reflects the cost of aligning employee incentives with shareholder interests and is a key component of total compensation strategy.

Ask your AI about Cronos Group's reportable segment — stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude